Preventing ischemic stroke: Current approaches to primary and secondary prevention

Postgraduate Medicine

Volumn 107, Issue 6, 2000, Pages

  Ingall, Timothy J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALTEPLASE; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ALCOHOL ABUSE; ANTICOAGULATION; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; OBESITY; RISK FACTOR; SLEEP APNEA SYNDROME; STROKE; TRANSIENT ISCHEMIC ATTACK; TREATMENT PLANNING;

EID: 0343962198     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2000.5.15.1087     Document Type: Conference Paper

References (37)

1. 2000 heart and stroke statistical update, Dallas: American Heart Assoc, 2000
2. Hademenos G. Metro Stroke Task Force: first-year experience. Stroke 1999;30(11):2512
3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: part II. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335(8693):827-38
4. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265(24):3255-64
5. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989;298(6676):789-94
6. Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for stroke: the Framingham Study. JAMA 1988; 259(7):1025-9
7. Warlow C. Endarterectomy for asymptomatic carotid stenosis? Lancet 1995;345(8960):1254-5
8. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995;273(18):1421-8
9. Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Semin Neurol 1998;18(4):429-40
10. Gorelick PB. Stroke prevention. Arch Neurol 1995;52(4):347-55
11. Hart RG, Sherman DG, Easton JD, et al. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998; 5l(3):674-81
12. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a metaanalysis. Ann Intern Med 1999;131(7):492-501
13. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized clinical trials. Arch Intern Med 1994;154(13):1449-57
14. Sacco RL, Gan R, Boden-Albala B, et al. Leisure-time physical activity and ischemic stroke risk: the Northern Manhattan Stroke Study. Stroke 1998;29(2):380-7
15. Abbott RD, Donahue RP, MacMahon SW, et al. Diabetes and the risk of stroke: the Honolulu Heart Program. JAMA 1987;257(7): 949-52
16. Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke? Am J Epidemiol 1988; 128(1):116-23
17. Demchuk AM, Hess DC, Brass LM, et al. Is cholesterol a risk factor for stroke? Yes. Arch Neurol 1999;56( 12):1518-20
18. Landau WM. Is cholesterol a risk factor for stroke? No. Arch Neurol 1999;56(12):1521-4
19. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934): 1383-9
20. Crouse JR 3d, Byington RP, Hoen HM, et al. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 157(12):1305-10
21. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials. Ann Intern Med 1998;128(2):89-95
22. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998;81(3):333-5
23. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation 1999;99(2):216-23
24. Whisnant JP. Natural history of transient ischemic attack and ischemic stroke. In: Whisnant JP, ed. Stroke: populations, cohorts, and clinical trials. Oxford: Butterworth Heinemann, 1993:135-53
25. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321(3):129-35
26. Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296(6618): 313-6
27. Dyken ML. Antiplatelet agents and stroke prevention. Semin Neurol 1998;18(4):441-50
28. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991;325(7):445-53
29. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998;339(20): 1415-25
30. European Carotid Surgery Trialists' Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial. Lancet 1998;351(9113):1379-87
31. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997;349(9065):1569-81
32. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet 1997;349(9006): 1641-9
33. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308(6921):81-106
34. van Gijn J, Algra A. Secondary stroke prevention with drugs: single or combined therapy? Cerebrovasc Dis 1999;9(Suppl 3):24-8
35. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143(1-2):1-13
36. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerbrovasc Dis 1995;5(3):147-57
37. SPAF Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 1998;279(16):1273-7